Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current HIV/AIDS Reports
Erschienen in: Current HIV/AIDS Reports 3/2016

28.04.2016 | Complications of Antiretroviral Therapy (G McComsey, Section Editor)

Non-infectious Pulmonary Diseases and HIV

verfasst von: M. Triplette, K. Crothers, E. F. Attia

Erschienen in: Current HIV/AIDS Reports | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Pulmonary complications remain among the most frequent causes of morbidity and mortality for individuals with HIV despite the advent of antiretroviral therapy (ART) and improvement in its efficacy and availability. The prevalence of non-infectious pulmonary diseases is rising in this population, reflecting both an increase in smoking and the independent risk associated with HIV. The unique mechanisms of pulmonary disease in these patients remain poorly understood, and direct effects of HIV, genetic predisposition, inflammatory pathways, and co-infections have all been implicated. Lung cancer, chronic obstructive pulmonary disease (COPD), and pulmonary hypertension are the most prevalent non-infectious pulmonary diseases in persons with HIV, and the risk of each of these diseases is higher among HIV-infected (HIV+) persons than in the general population. This review discusses the latest advances in the literature on these important complications of HIV infection.
Literatur
1.
2.
Engels EA, Brock MV, Chen J, et al. Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol. 2006;24:1383–8.CrossRefPubMed
3.
Crothers K, Butt AA, Gibert CL, et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest. 2006;130:1326–33.CrossRefPubMed
4.
Gingo MR, George MP, Kessinger CJ, et al. Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. Am J Respir Crit Care Med. 2010;182:790–6.CrossRefPubMedPubMedCentral
5.
Rossouw TM, Anderson R, Feldman C. Impact of HIV infection and smoking on lung immunity and related disorders. Eur Respir J. 2015;46:1781–95.CrossRefPubMed
6.
Kirk GD, Merlo C, O’Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007;45:103–10.CrossRefPubMedPubMedCentral
7.
Robbins HA, Pfeiffer RM, Shiels MS, et al. Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst 2015;107. 10.​1093/​jnci/​dju503. Print 2015 Apr.
8.
9.
10.
Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015;163:507–18.CrossRefPubMedPubMedCentral
11.•
Sigel K, Wisnivesky J, Gordon K, et al. HIV as an independent risk factor for incident lung cancer. AIDS. 2012;26:1017–25. The authors examined a large cohort of 37,294 HIV-infected Veterans compared to 75,750 uninfected Veterans with excellent follow-up to compare the incidence of lung cancer. In models adjusted for smoking and other potential confounding factors, they estimated the adjusted incidence rate ratio of lung cancer associated with HIV to be 1.7 95% CI:(1.5–1.9), suggesting an independent risk of lung cancer in HIV.
12.
13.
14.
Silverberg MJ, Chao C, Leyden WA, et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2551–9.CrossRefPubMedPubMedCentral
15.
Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer. 2010;116:5306–15.CrossRefPubMed
16.
Kesselring A, Gras L, Smit C, et al. Immunodeficiency as a risk factor for non-AIDS-defining malignancies in HIV-1-infected patients receiving combination antiretroviral therapy. Clin Infect Dis. 2011;52:1458–65.CrossRefPubMed
17.
Hessol NA, Martinez-Maza O, Levine AM, et al. Lung cancer incidence and survival among HIV-infected and uninfected women and men. AIDS. 2015;29:1183–93.CrossRefPubMed
18.
Collini P, Morris A. Maintaining lung health with longstanding HIV. Curr Opin Infect Dis. 2016;29:31–8.CrossRefPubMed
19.
Kawabata S, Heredia A, Gills J, et al. Impact of HIV on lung tumorigenesis in an animal model. AIDS. 2015;29:633–5.PubMed
20.
Androutsopoulos VP, Tsatsakis AM, Spandidos DA. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer. 2009;9:187. 2407-9-187.CrossRefPubMedPubMedCentral
21.
Bruyand M, Le Marec F, Lavole A, et al. Protease inhibitors exposure is not related to lung cancer risk in HIV smoker patients: a nested case-control study. AIDS. 2015;29:1105–9.CrossRefPubMed
22.
Bruyand M, Ryom L, Shepherd L, et al. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D:A:D study. J Acquir Immune Defic Syndr. 2015;68:568–77.CrossRefPubMed
23.
Team NLSTR, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395–409.CrossRef
24.
Sigel K, Wisnivesky J, Shahrir S, et al. Findings in asymptomatic HIV-infected patients undergoing chest computed tomography testing: implications for lung cancer screening. AIDS. 2014;28:1007–14.CrossRefPubMedPubMedCentral
25.
Hulbert A, Hooker CM, Keruly JC, et al. Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol. 2014;9:752–9.CrossRefPubMedPubMedCentral
26.•
Makinson A, Eymard-Duvernay S, Raffi F, et al. Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers. AIDS. 2016;30:573–82. The risks and benefits of lung cancer screening were assessed in this single arm trial of chest CT in a subset of HIV-infected smokers in France. Patients were eligible for enrollment if they were older than 40, had a smoking history of at least 20 pack-years and had a CD4 cell count below 350. 442 patients were enrolled and underwent chest CT with ultimate prevalence of lung cancer of 2.03% (95% CI: 0.90-3.80) translating to a number needed to screen of 49 (95% CI: 26-111). No serious adverse events from procedures related to screening were reported. This suggests a possible benefit of screening for lung cancer in a subset of HIV-infected patients.CrossRefPubMed
27.
28.
Brugnaro P, Morelli E, Cattelan F, et al. Non-AIDS definings malignancies among human immunodeficiency virus-positive subjects: epidemiology and outcome after two decades of HAART era. World J Virol. 2015;4:209–18.CrossRefPubMedPubMedCentral
29.
Marcus JL, Chao C, Leyden WA, et al. Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers. Cancer Epidemiol Biomarkers Prev. 2015;24:1167–73.CrossRefPubMed
30.
Suneja G, Shiels MS, Angulo R, et al. Cancer treatment disparities in HIV-infected individuals in the United States. J Clin Oncol. 2014;32:2344–50.CrossRefPubMedPubMedCentral
31.•
Coghill AE, Shiels MS, Suneja G, et al. Elevated cancer-specific mortality among HIV-infected patients in the United States. J Clin Oncol. 2015;33:2376–83. This large cohort study, linking HIV/AIDS and cancer registries in 6 states, determined differences in cancer-specific mortality by HIV status. After adjustment for demographic features, cancer stage and diagnosis year, among those with lung cancer the estimated hazard ratio for cancer specific mortality was 1.28 (95% CI 1.17-1.39) comparing HIV-infected to uninfected patients. This suggests higher lung cancer-specific mortality in HIV, although it is unclear if this would persist with finer adjustment for other confounding variables.CrossRefPubMed
32.
Rengan R, Mitra N, Liao K, et al. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol. 2012;13:1203–9.CrossRefPubMed
33.
34.
Thun M, Peto R, Boreham J, et al. Stages of the cigarette epidemic on entering its second century. Tob Control. 2012;21:96–101.CrossRefPubMed
35.
36.
Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med. 2011;62:157–70.CrossRefPubMed
37.
Petoumenos K, Hui E, Kumarasamy N, et al. Cancers in the TREAT Asia HIV Observational Database (TAHOD): a retrospective analysis of risk factors. J Int AIDS Soc. 2010;13:51. 2652-13-51.CrossRefPubMedPubMedCentral
38.
Mutyaba I, Phipps W, Krantz EM, et al. A Population-level evaluation of the effect of antiretroviral therapy on cancer incidence in Kyadondo County, Uganda, 1999–2008. J Acquir Immune Defic Syndr. 2015;69:481–6.CrossRefPubMed
39.
Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer. 2006;118:985–90.CrossRefPubMed
40.
Jaquet A, Odutola M, Ekouevi DK, et al. Cancer and HIV infection in referral hospitals from four West African countries. Cancer Epidemiol. 2015;39:1060–5.CrossRefPubMed
41.
George MP, Kannass M, Huang L, et al. Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. PLoS One. 2009;4:e6328.CrossRefPubMedPubMedCentral
42.
Samperiz G, Guerrero D, Lopez M, et al. Prevalence of and risk factors for pulmonary abnormalities in HIV-infected patients treated with antiretroviral therapy. HIV Med. 2014;15:321–9.CrossRefPubMed
43.
Makinson A, Hayot M, Eymard-Duvernay S, et al. High prevalence of undiagnosed COPD in a cohort of HIV-infected smokers. Eur Respir J. 2015;45:828–31.CrossRefPubMed
44.
Gingo MR, Balasubramani GK, Rice TB, et al. Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts. BMC Pulm Med. 2014;14:75. 2466-14-75.CrossRefPubMedPubMedCentral
45.
Drummond MB, Kirk GD, Astemborski J, et al. Association between obstructive lung disease and markers of HIV infection in a high-risk cohort. Thorax. 2012;67:309–14.CrossRefPubMedPubMedCentral
46.
Drummond MB, Merlo CA, Astemborski J, et al. The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS. 2013;27:1303–11.CrossRefPubMedPubMedCentral
47.
Simonetti JA, Gingo MR, Kingsley L, et al. Pulmonary function in HIV-infected recreational drug users in the era of anti-retroviral therapy. J AIDS Clin Res. 2014;5:365.CrossRefPubMedPubMedCentral
48.
Rahmanian SD, Wood KL, Lin S, et al. Gender differences in pulmonary function, respiratory symptoms, and macrophage proteomics among HIV-infected smokers. Scientifica (Cairo). 2014;2014:613689.
49.
Gingo MR, Balasubramani GK, Kingsley L, et al. The impact of HAART on the respiratory complications of HIV infection: longitudinal trends in the MACS and WIHS cohorts. PLoS One. 2013;8:e58812.CrossRefPubMedPubMedCentral
50.
Kunisaki KM, Niewoehner DE, Collins G, et al. Pulmonary function in an international sample of HIV-positive, treatment-naive adults with CD4 counts >500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med. 2015;16 Suppl 1:119–28.CrossRefPubMedPubMedCentral
51.•
Popescu I, Drummond MB, Gama L, et al. Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190:744–55. This study examined markers of T-cell immunity in peripheral blood and bronchoalveolar lavage fluid using flow cytometry comparing HIV-infected patients with COPD to HIV-infected patients without COPD and uninfected patients with COPD. They found that lung mucosal CD4 T-cell deletion and HIV-specific lung mucosal immune dysregulation were associated with COPD in HIV, adding evidence that lung-specific immune dysfunction is related to the development of COPD in HIV.CrossRefPubMedPubMedCentral
52.
53.
Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185:1073–80.CrossRefPubMedPubMedCentral
54.
55.•
Cui L, Lucht L, Tipton L, et al. Topographic diversity of the respiratory tract mycobiome and alteration in HIV and lung disease. Am J Respir Crit Care Med. 2015;191:932–42. In this study, respiratory tract specimens from 56 patients were sequenced to examine the fungal microbiome comparing HIV-infected and uninfected subjects with and without COPD. There were significant differences in fungal communities in the lavage fluid by HIV and COPD status and over-representation of Pneumocystis jirovecii was observed in both these groups. This study suggests that alterations in the fungal microbiome may link lung dysfunction and HIV. Future studies of the microbiome in HIV-related COPD hold great promise to further elucidate the pathophysiology of chronic lung disease in this population.
56.
Lozupone C, Cota-Gomez A, Palmer BE, et al. Widespread colonization of the lung by Tropheryma whipplei in HIV infection. Am J Respir Crit Care Med. 2013;187:1110–7.CrossRefPubMedPubMedCentral
57.
Diaz PT, King MA, Pacht ER, et al. The pathophysiology of pulmonary diffusion impairment in human immunodeficiency virus infection. Am J Respir Crit Care Med. 1999;160:272–7.CrossRefPubMed
58.
59.
Diaz PT, Wewers MD, Pacht E, et al. Respiratory symptoms among HIV-seropositive individuals. Chest. 2003;123:1977–82.CrossRefPubMed
60.
Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med. 2000;132:369–72.CrossRefPubMed
61.
Crothers K, McGinnis K, Kleerup E, et al. HIV infection is associated with reduced pulmonary diffusing capacity. J Acquir Immune Defic Syndr. 2013;64:271–8.CrossRefPubMed
62.
Guaraldi G, Besutti G, Scaglioni R, et al. The burden of image based emphysema and bronchiolitis in HIV-infected individuals on antiretroviral therapy. PLoS One. 2014;9:e109027.CrossRefPubMedPubMedCentral
63.
Petrache I, Diab K, Knox KS, et al. HIV associated pulmonary emphysema: a review of the literature and inquiry into its mechanism. Thorax. 2008;63:463–9.CrossRefPubMed
64.
Attia EF, Akgun KM, Wongtrakool C, et al. Increased risk of radiographic emphysema in HIV is associated with elevated soluble CD14 and nadir CD4. Chest. 2014;146:1543–53.CrossRefPubMedPubMedCentral
65.
Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med. 2014;35:71–86.CrossRefPubMed
66.
Besutti G, Raggi P, Zona S, et al. Independent association of subclinical coronary artery disease and emphysema in HIV-infected patients. HIV Med 2015.
67.
Liu JC, Leung JM, Ngan DA, et al. Absolute leukocyte telomere length in HIV-infected and uninfected individuals: evidence of accelerated cell senescence in HIV-associated chronic obstructive pulmonary disease. PLoS One. 2015;10:e0124426.CrossRefPubMedPubMedCentral
68.
Campo M, Oursler KK, Huang L, et al. Association of chronic cough and pulmonary function with 6-minute walk test performance in HIV infection. J Acquir Immune Defic Syndr. 2014;65:557–63.CrossRefPubMedPubMedCentral
69.
Attia EF, McGinnis KA, Feemster LC, et al. Association of COPD with risk for pulmonary infections requiring hospitalization in HIV-infected veterans. J Acquir Immune Defic Syndr. 2015;70:280–8.CrossRefPubMed
70.
Lambert AA, Kirk GD, Astemborski J, et al. HIV infection is associated with increased risk for acute exacerbation of COPD. J Acquir Immune Defic Syndr. 2015;69:68–74.CrossRefPubMedPubMedCentral
71.
Depp TB, McGinnis KA, Kraemer K, et al. Risk factors associated with acute exacerbation of chronic obstructive pulmonary disease in HIV-infected and uninfected patients. AIDS. 2016;30:455–63.PubMed
72.
73.
Finney LJ, Feary JR, Leonardi-Bee J, et al. Chronic obstructive pulmonary disease in sub-Saharan Africa: a systematic review. Int J Tuberc Lung Dis. 2013;17:583–9.CrossRefPubMed
74.
Bloomfield GS, Khazanie P, Morris A, et al. HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research. J Acquir Immune Defic Syndr. 2014;67 Suppl 1:S40–53.CrossRefPubMedPubMedCentral
75.
76.
Pefura-Yone EW, Fodjeu G, Kengne AP, et al. Prevalence and determinants of chronic obstructive pulmonary disease in HIV infected patients in an African country with low level of tobacco smoking. Respir Med. 2015;109:247–54.CrossRefPubMed
77.
Pacek LR, Cioe PA. Tobacco use, use disorders, and smoking cessation interventions in persons living with HIV. Curr HIV/AIDS Rep. 2015;12:413–20.CrossRefPubMed
78.
Isasti G, Moreno T, Perez I, et al. High prevalence of pulmonary arterial hypertension in a cohort of asymptomatic HIV-infected patients. AIDS Res Hum Retroviruses. 2013;29:231–4.CrossRefPubMed
79.
80.
Butrous G. Human immunodeficiency virus-associated pulmonary arterial hypertension: considerations for pulmonary vascular diseases in the developing world. Circulation. 2015;131:1361–70.CrossRefPubMed
81.
Tcherakian C, Couderc LJ, Humbert M, et al. Inflammatory mechanisms in HIV-associated pulmonary arterial hypertension. Semin Respir Crit Care Med. 2013;34:645–53.CrossRefPubMed
82.
Feijoo MQ, Toro R, Lopez Vazquez de la Torre M, et al. Relationship between endothelin-1 levels and pulmonary arterial hypertension in HIV-infected patients. AIDS. 2014;28:2693–9.CrossRefPubMed
83.
Parikh RV, Scherzer R, Nitta EM, et al. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection. AIDS. 2014;28:511–9.CrossRefPubMedPubMedCentral
84.
George MP, Champion HC, Simon M, et al. Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertension. Am J Respir Cell Mol Biol. 2013;48:374–81.CrossRefPubMedPubMedCentral
85.
Dellegrottaglie S, Garcia-Alvarez A, Guarini P, et al. Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension. Heart Lung. 2014;43:256–61.CrossRefPubMed
86.
Isiguzo GC, Okeahialam BN, Danbauchi SS, et al. Contributions of pulmonary hypertension to HIV-related cardiac dysfunction. Indian Heart J. 2013;65:644–9.CrossRefPubMedPubMedCentral
87.
Dalvi P, Wang K, Mermis J, et al. HIV-1/cocaine induced oxidative stress disrupts tight junction protein-1 in human pulmonary microvascular endothelial cells: role of Ras/ERK1/2 pathway. PLoS One. 2014;9:e85246.CrossRefPubMedPubMedCentral
88.
George MP, Champion HC, Gladwin MT, et al. Injection drug use as a “second hit” in the pathogenesis of HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2012;185:1144–6.CrossRefPubMedPubMedCentral
89.
Spikes L, Dalvi P, Tawfik O, et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med. 2012;185:1235–43.CrossRefPubMedPubMedCentral
90.
Correale M, Palmiotti GA, Lo Storto MM, et al. HIV-associated pulmonary arterial hypertension: from bedside to the future. Eur J Clin Invest. 2015;45:515–28.CrossRefPubMed
91.
Degano B, Guillaume M, Savale L, et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS. 2010;24:67–75.CrossRefPubMed
92.
Li Y, Li XH, Yu ZX, et al. HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension. Pulm Circ. 2015;5:538–46.CrossRefPubMedPubMedCentral
93.•
Amsellem V, Lipskaia L, Abid S, et al. CCR5 as a treatment target in pulmonary arterial hypertension. Circulation. 2014;130:880–91. This study used a mouse model to explore the effect of CCR5, a receptor for cellular HIV entry present in both macrophages and vascular cells, on pulmonary arterial hypertension. The investigators used both gene disruption and pharmacologic methods (using the CCR5 antagonist maraviroc) to inactivate the CCR5 receptor. When exposed to hypoxic conditions, the CCR5 inactive mice demonstrated decreased inflammatory responses and proliferation of pulmonary artery smooth muscle, both of which are associated with the development of pulmonary hypertension. This study highlights the potential role of the CCR5 pathway in pulmonary hypertension and suggests a possible benefit of maraviroc in patients with HIV-associated pulmonary hypertension.
94.
Thienemann F, Sliwa K, Rockstroh JK. HIV and the heart: the impact of antiretroviral therapy: a global perspective. Eur Heart J. 2013;34:3538–46.CrossRefPubMed
95.
Bigna JJ, Sime PS, Koulla-Shiro S. HIV related pulmonary arterial hypertension: epidemiology in Africa, physiopathology, and role of antiretroviral treatment. AIDS Res Ther. 2015;12:36. 015-0078-3. eCollection 2015.CrossRefPubMedPubMedCentral
96.
Syed FF, Sani MU. Recent advances in HIV-associated cardiovascular diseases in Africa. Heart. 2013;99:1146–53.CrossRefPubMed
97.
Chillo P, Bakari M, Lwakatare J. Echocardiographic diagnoses in HIV-infected patients presenting with cardiac symptoms at Muhimbili National Hospital in Dar es Salaam, Tanzania. Cardiovasc J Afr. 2012;23:90–7.CrossRefPubMedPubMedCentral
98.
Kolosionek E, Crosby A, Harhay MO, et al. Pulmonary vascular disease associated with schistosomiasis. Expert Rev Anti Infect Ther. 2010;8:1467–73.CrossRefPubMed
99.
Kolosionek E, King J, Rollinson D, et al. Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: detailed study. Pulm Circ. 2013;3:356–62.CrossRefPubMedPubMedCentral
100.
Kariuki W, Manuel JI, Kariuki N, et al. HIV and smoking: associated risks and prevention strategies. HIV AIDS (Auckl). 2015;8:17–36.
101.
Keith A, Dong Y, Shuter J, et al. Behavioral interventions for tobacco use in HIV-infected smokers: a meta-analysis. J Acquir Immune Defic Syndr 2016.
Metadaten
Titel
Non-infectious Pulmonary Diseases and HIV
verfasst von
M. Triplette
K. Crothers
E. F. Attia
Publikationsdatum
28.04.2016
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 3/2016
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-016-0313-0

Weitere Artikel der Ausgabe 3/2016

Current HIV/AIDS Reports 3/2016 Zur Ausgabe

The Global Epidemic (SH Vermund, Section Editor)

Integrating Human Immunodeficiency Virus and Reproductive, Maternal and Child, and Tuberculosis Health Services Within National Health Systems

The Global Epidemic (SH Vermund, Section Editor)

Factors Driving the HIV Epidemic in Southern Africa

The Science of Prevention (JD Stekler and J Baeten, Section Editors)

PrEP as Peri-conception HIV Prevention for Women and Men

Complications of Antiretroviral Therapy (G McComsey, Section Editor)

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments

The Global Epidemic (SH Vermund, Section Editor)

Understanding Sustained Retention in HIV/AIDS Care and Treatment: a Synthetic Review

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 | Hypertonie | Nachrichten

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise